OS Therapies' Phase 2b trial of OST-HER2 met its primary endpoint, demonstrating a statistically significant improvement in 12-month Event Free Survival in recurrent osteosarcoma patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.